BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ARQ 197: Phase I/II started

ArQule began a double-blind, placebo-controlled Phase I/II trial to evaluate irinotecan and cetuximab with or without ARQ 197. ArQule is co-developing ARQ 197 with Daiichi on a worldwide basis outside of certain Asian countries where ArQule licensed...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >